Clinical Pearls For Heart Failure

Discussion in 'General Discussion' started by The Good Doctor, Apr 15, 2021.

  1. The Good Doctor

    The Good Doctor Golden Member

    Joined:
    Aug 12, 2020
    Messages:
    7,454
    Likes Received:
    5
    Trophy Points:
    11,970
    Gender:
    Female

    Stay sharp with the latest research in Cardiology and heart failure with Smartest Doc.

    [​IMG]

    • Canagliflozin improves outcomes in patients with type 2 diabetes and CKD regardless of the presence of heart failure.

    • Adding ivabradine to standard therapies improves cardiac function in patients with chronic heart failure.

    • Soluble ST2 and catestatin levels predict in-hospital mortality in patients with acute worsening of heart failure.

    • RV strain helps predict outcomes in patients with heart failure and preserved ejection fraction.

    • Lipid profiling may capture preclinical molecular alterations that predispose for incident HF.

    • Ischemic heart disease adversely impacts the clinical course of HFpEF.

    • Catheter ablation of AF improves outcomes in patients with HF.

    • Frailty is highly prevalent in HFrEF.

    • Methamphetamine use is associated with systolic dysfunction.

    • Cardiac fibrosis is increased in heart failure.

    • CHF hospitalization in patients with AF is a poor prognostic marker.

    • Empagliflozin improves heart failure outcomes across the range of kidney function.

    • Galectin-3 levels are not associated with risk of incident HF in patients with chronic kidney disease.

    • Heart failure risk from systemic lupus erythematosus is greatest at younger ages.

    • A history of prior MI is tied to a greater risk of CV death in patients with heart failure and preserved ejection fraction.

    • HF risk scores have comparable performance in men and women.

    • Hypothyroidism doesn't affect mortality risk in patients receiving cardiac resynchronization therapy for heart failure.

    • Failure of noninvasive ventilation increases in the risk of in-hospital mortality in patients with acute heart failure.

    • A smoking history worsens CV outcomes in patients with heart failure and reduced, but not preserved, ejection fraction.

    • Sacubitril-valsartan is superior to ACE-inhibitors and ARBs for patients with heart failure.

    • LV hypertrophy on ECG predicts heart failure hospitalization in middle-age women but not men.

    • The coexistence of multiple frailty domains is common in elderly patients hospitalized with heart failure.

    • Mortality is higher among patients with advanced heart failure living in rural vs urban areas.

    • Soluble ST2 and catestatin levels predict in-hospital mortality in patients with acute worsening of heart failure.

    • RV strain helps predict outcomes in patients with heart failure and preserved ejection fraction.

    • The urinary proteomic classifier HF1 performs as well as BNP for the diagnosis of heart failure.

    • Methotrexate lowers heart failure risk in patients with rheumatoid arthritis.

    • High levels of parathyroid hormone and fibroblast growth factor-23 predict incident heart failure.

    • Statins reduce neurological events in advanced heart failure patients implanted with LV assist systems.

    • A history of prior MI is tied to a greater risk of CV death in patients with heart failure and preserved ejection fraction.
    Source
     

    Add Reply

Share This Page

<